A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs CB 5083 (Primary)
  • Indications Primitive neuroectodermal tumours; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cleave Biosciences
  • Most Recent Events

    • 27 Feb 2018 Status changed from active, no longer recruiting to discontinued.
    • 15 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2016 Planned number of patients changed from 75 to 150.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top